Safety and efficacy of non-medical switch from innovator to generic tofacitinib: a 3-month observational study in rheumatoid arthritis patients
- 1Rheumatology Unit, Department of Medicine, Hospital Raja Permaisuri Bainun, Ipoh 30450, Malaysia
- 2Rheumatology Unit, Department of Medicine, Tuanku Ja’afar Hospital, Seremban 70300, Malaysia
- 3Department of Medicine, Hospital Kuala Kangsar, Kuala Kangsar 33000, Malaysia
Abstract
Aim: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by systemic inflammation. Following the expiry of the patent for innovator tofacitinib (Xeljanz), generic tofacitinib formulations such as Tozib have become available. This study evaluated the impact of a non-medical switch from innovator tofacitinib to generic tofacitinib on disease activity and flare rates over 3 months in patients with RA. Methods: This retrospective multicenter observational study in Malaysia included 36 patients with RA in remission or low disease activity who underwent a non-medical switch from innovator to generic tofacitinib. Disease activity was assessed at baseline and 3 months using the Disease Activity Score-28 erythrocyte sedimentation rate (DAS28-ESR). Flare was defined as an increase in DAS28-ESR of ≥ 1.2, or ≥ 0.6 if the concurrent DAS28-ESR was ≥ 3.2. Results: Thirty-six patients with RA who switched from reference medication to generic tofacitinib were included; 88.9% were female, with a mean age of 64.1 ± 9.4 years. Patients had longstanding disease, with a median disease duration of 15.5 years (IQR 8.8–19.0), and had received originator tofacitinib for a mean duration of 3.48 ± 1.71 years prior to switching. At 3 months post-switch, disease activity remained stable, with no significant change in median DAS28-ESR from 2.17 (IQR 1.19) to 2.45 (IQR 1.03) (p = 0.141). Although 16.7% of patients showed a DAS28-ESR increase of ≥ 0.6, none had DAS28-ESR ≥ 3.2 at 3 months. Only one patient demonstrated a DAS28-ESR change ≥ 1.2 after switching, with no new safety concerns observed. Conclusions: Our findings suggest that non-medical switching from reference medication to generic tofacitinib did not significantly affect short-term disease control or safety in RA patients over a 3-month follow-up period. These results provide preliminary real-world evidence supporting generic substitution; however, further studies with larger sample sizes and longer follow-up are warranted.
Related
- Co-Occurrence Patterns of Symptom and Functional Burden Associated with Tofacitinib and Upadacitinib: A Multidimensional Analysis of Spontaneous Reports in Rheumatoid Arthritis.
- Efficacy, mechanisms, and influence factors of small molecule targeted therapy in treating rheumatoid arthritis: a multi-dimensional clinical, immunological, and ultrasonographic study
- Leukocyte-Poor Platelet-Rich Plasma in Foot and Ankle Tendinopathies in Patients With Spondyloarthritis and Rheumatoid Arthritis: A Dual-Center Observational Study
- Evaluation of the efficacy of Si-based agent in Rheumatoid Arthritis with complicating vestibular impairment
- Effectiveness, safety and persistence of filgotinib in rheumatoid arthritis with a specific focus on difficult-to-treat patients: results from a multicentre observational study.
BibTeX
@article{ong2026safety,
title = {{Safety and efficacy of non-medical switch from innovator to generic tofacitinib: a 3-month observational study in rheumatoid arthritis patients}},
author = {Ping Seung Ong and Manisha Chandran and Avreena Kaur Bhullar},
journal = {Exploration of Musculoskeletal Diseases},
year = {2026},
month = oct,
doi = {10.37349/emd.2026.1007137},
url = {https://doi.org/10.37349/emd.2026.1007137},
note = {CC BY},
}
RIS
TY - JOUR
TI - Safety and efficacy of non-medical switch from innovator to generic tofacitinib: a 3-month observational study in rheumatoid arthritis patients
AU - Ping Seung Ong
AU - Manisha Chandran
AU - Avreena Kaur Bhullar
PY - 2026
DA - 2026/10/01
JO - Exploration of Musculoskeletal Diseases
DO - 10.37349/emd.2026.1007137
UR - https://doi.org/10.37349/emd.2026.1007137
AB - Aim: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by systemic inflammation. Following the expiry of the patent for innovator tofacitinib (Xeljanz), generic tofacitinib formulations such as Tozib have become available. This study evaluated the impact of a non-medical switch from innovator tofacitinib to generic tofacitinib on disease activity and flare rates over 3 months in patients with RA. Methods: This retrospective multicenter observational study in Malaysia included 36 patients with RA in remission or low disease activity who underwent a non-medical switch from innovator to generic tofacitinib. Disease activity was assessed at baseline and 3 months using the Disease Activity Score-28 erythrocyte sedimentation rate (DAS28-ESR). Flare was defined as an increase in DAS28-ESR of ≥ 1.2, or ≥ 0.6 if the concurrent DAS28-ESR was ≥ 3.2. Results: Thirty-six patients with RA who switched from reference medication to generic tofacitinib were included; 88.9% were female, with a mean age of 64.1 ± 9.4 years. Patients had longstanding disease, with a median disease duration of 15.5 years (IQR 8.8–19.0), and had received originator tofacitinib for a mean duration of 3.48 ± 1.71 years prior to switching. At 3 months post-switch, disease activity remained stable, with no significant change in median DAS28-ESR from 2.17 (IQR 1.19) to 2.45 (IQR 1.03) (p = 0.141). Although 16.7% of patients showed a DAS28-ESR increase of ≥ 0.6, none had DAS28-ESR ≥ 3.2 at 3 months. Only one patient demonstrated a DAS28-ESR change ≥ 1.2 after switching, with no new safety concerns observed. Conclusions: Our findings suggest that non-medical switching from reference medication to generic tofacitinib did not significantly affect short-term disease control or safety in RA patients over a 3-month follow-up period. These results provide preliminary real-world evidence supporting generic substitution; however, further studies with larger sample sizes and longer follow-up are warranted.
SN - 2836-6468
ER -